Biotech firm Orphazyme reports that it has to cut two thirds of its workforce and bid three of its board members farewell.
This is because the US Food and Drug Administration (FDA) rejected the company's main drug candidate for treating Niemann-Pick type C (NPC) earlier in June.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Biostatistician 
Clinical Project Manager 
Senior Manager, Clinical Trial Budget 
Director for innovative pre-clinical testing unit 
2 Sales Representatives and Product Specialists 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Procurement Manager, Direct Materials 
Client Talent Acquisition Specialist 
Cell Culture Scientist/Senior Scientist 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Director Global Engineering 
Key Account Manager, Europe and Asia 
Nordic Medical Affairs Manager 
(Senior) Drug Substance Specialist 
Project Manager & Scrum Master